ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 116-119

  Ohshiro, Muneo ^a   Kuroda, Junya ^a   Kobayashi, Yutaka ^b   Akaogi, Teruaki ^b   Kawata, Eri ^b   Uoshima, Nobuhiko ^c   Kamitsuji, Yuri ^c   Kaneko, Hiroto ^d,e   Shimura, Kazuho ^d   Shimazaki, Chihiro ^f   Murakami, Satoshi ^f   Hatsuse, Mayumi ^f   Okano, Akira ^f   Kobayashi, Tsutomu ^a   Uchiyama, Hitoji ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^c MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^d Aiseikai Yamashina Hospital   (Japan)

^e KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^f Kyoto Social Insurance Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CREATININE; DISINTEGRIN; FIBRIN MONOMER; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FRESH FROZEN PLASMA; HIGH MOBILITY GROUP B1 PROTEIN; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; RECOMBINANT THROMBOMODULIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LYMPHOMA; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; REMISSION; SURVIVAL; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADAM PROTEINS; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMATOLOGIC NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOMODULIN;

EID: 84155162798     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22185     Document Type: Letter

References (30)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
2. Toh CH, Dennis M. Disseminated intravascular coagulation: Old disease, new hope. BMJ 2003; 327: 974-977.
3. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005; 128: 2864-2875.
4. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
5. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-371.
6. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002; 196: 561-564.
7. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
8. Ito T, Kawahara K, Okamoto K, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008; 28: 1825-1830.
9. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
10. Kobayashi N, Maekawa T, Takada M, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1983; 49: 265-275.
11. Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125: 6-11.
12. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
13. Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
14. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS-13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
15. Crawley JT, Lam JK, Rance JB, et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-1093.
16. Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35: 2375-2382.
17. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-140.
18. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS-13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006; 107: 528-534.
19. Lam JK, Chion CK, Zanardelli S, et al. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost 2007; 5: 1010-1018.
20. Hyun J, Kim HK, Kim JE, et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb Res 2009; 124: 75-79.
21. Kiss JE. Thrombotic thrombocytopenic purpura: Recognition and management. Int J Hematol 2010; 91: 36-45.
22. Lämmle B, Kremer Hovinga JA, et al. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008; 93: 172-177.
23. Noris P, Balduini CL. Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opin Investig Drugs 2011; 20: 1087-1098.
24. Ostermann H. Antithrombin III in sepsis. New evidences and open questions. Minerva Anestesiol 2002; 68: 445-448.
25. Cauchie P, Cauchie Ch, Boudjeltia KZ, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital-Meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006; 81: 414-419.
26. Dempfle CE, Wurst M, Smolinski M, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 2004; 91: 812-818.
27. Kim HK, Lee DS, Kang SH, et al. Utility of the fibrinogen/C-reactive protein ratio for the diagnosis of disseminated intravascular coagulation. Acta Haematol 2007; 117: 34-39.
28. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979.
29. Kotajima N, Kanda T, Fukumura Y, et al. Serum thrombomodulin as a prognostic marker of disseminated intravascular coagulation. J Med 1999; 30: 19-29.
30. Gando S, Kameue T, Nanzaki S, et al. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-228.